Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Total Current Liabilities (2018 - 2025)

Historic Total Current Liabilities for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to $38.9 million.

  • Dna X's Total Current Liabilities rose 2073.08% to $38.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.9 million, marking a year-over-year increase of 2073.08%. This contributed to the annual value of $43.7 million for FY2024, which is 3606.25% up from last year.
  • According to the latest figures from Q3 2025, Dna X's Total Current Liabilities is $38.9 million, which was up 2073.08% from $35.7 million recorded in Q2 2025.
  • In the past 5 years, Dna X's Total Current Liabilities registered a high of $43.7 million during Q4 2024, and its lowest value of $19.9 million during Q1 2021.
  • For the 5-year period, Dna X's Total Current Liabilities averaged around $29.5 million, with its median value being $29.7 million (2023).
  • As far as peak fluctuations go, Dna X's Total Current Liabilities crashed by 2932.71% in 2024, and later soared by 6532.54% in 2025.
  • Dna X's Total Current Liabilities (Quarter) stood at $21.0 million in 2021, then surged by 52.79% to $32.1 million in 2022, then rose by 0.27% to $32.1 million in 2023, then skyrocketed by 36.06% to $43.7 million in 2024, then decreased by 11.17% to $38.9 million in 2025.
  • Its Total Current Liabilities stands at $38.9 million for Q3 2025, versus $35.7 million for Q2 2025 and $34.7 million for Q1 2025.